Patent application number | Description | Published |
20130084575 | METHOD AND DEVICE FOR REPLICATING A CELL COLONY IN CULTURE FOR EARLY ANALYSIS - The present invention provides an apparatus comprising, in combination: (a) a cell culture plate, the cell culture plate comprising a first substrate and a plurality of cell carriers on the substrate in a first pattern; and (b) a cell replication plate, the cell replication plate comprising a second substrate and a plurality of cell sampling posts on the second substrate in a second pattern corresponding to the first pattern. Each of the sampling posts is configured to align with a respective one of the cell carriers in a position in which cells growing on the cell carrier propagate onto the sampling post; so that a plurality of distinct cell colonies growing on the cell culture plate are replicated on the cell replication plate. Methods of using the same are also described. | 04-04-2013 |
20130101505 | Stable Activatable Particles as Radiotherapeutic Agents for the Treatment of Disease - The present invention provides radiotherapeutic agents and compositions and methods for making and using the same. In some embodiments, the radiotherapeutic agent is a nanoparticle comprising a radionuclide and a carrier moiety. In some embodiments, the radionuclide is produced by activating a stable activatable particle via neutron activation. | 04-25-2013 |
20130123097 | SUPPORTED IRIDIUM CATALYSTS - A method of converting at least one first alkane to a mixture of at least one low molecular weight alkane (optionally also including additional lower and/or higher molecular weight alkanes) and at least one high molecular weight alkane, comprises: reacting a first alkane in the presence of dual catalyst system comprising a first catalyst (i.e., a hydrogen transfer catalyst) and a second catalyst (i.e., a metathesis catalyst) to produce a mixture of low and high molecular weight alkanes. | 05-16-2013 |
20130125714 | SCREW HOLDER-DRIVER APPARATUSES, SYSTEMS AND METHODS - Screw driver-holder apparatuses, systems and methods are provided and can include a screw and a screwdriver. The screw can include a threaded screw body and a screw head, and the screw head can include a socket and a screw head surface surrounding the socket. The screwdriver can include a hollow sleeve with a longitudinal bore and a first end defining a screw engagement surface and a driving shaft positioned within the longitudinal bore of the hollow sleeve and rotatable relative to the hollow sleeve. The driving shaft can further include a first end extending beyond the first end of the hollow sleeve, a second end opposite the first end, and a stop restricting axial movement of the sleeve towards the second end of the driving shaft. The first end can include a protruding tip adapted for engaging the socket of the screw head. | 05-23-2013 |
20130131678 | THREADED ELASTIC INTRAMEDULLARY NAILS DEVICES AND METHODS - Devices and methods for treating fractures using intramedullary nails and screws are provided. An intramedullary nail and fixation device can be capable of holding a bone out to length when it is broken in a manner that allows shortening of and/or compressing a bone to promote healing. The device can include a flexible nail with a first leading end and a second end, the nail having a threaded outer surface along at least a portion of a length of the nail. A method for treatment of fractures of long bones having a medullary canal can include creating a hole into an end of a bone to be compressed, inserting a leading end of such a flexible nail into the hole, and rotating the nail to advance the nail through the medullary canal. | 05-23-2013 |
20130177921 | Detection of Damage to DNA - The present invention relates to methods of assessing damage to cellular DNA including the type, frequency and/or distribution of the DNA damage in the genome. The invention further provides methods of evaluating DNA damage in a cell caused by an agent and/or event as well as methods of determining a subject's prior exposure to an agent and/or event that is known or suspected to cause DNA damage. Further provided are methods of determining whether a subject is at an increased risk for a disease or disorder as a result of cellular DNA damage. | 07-11-2013 |
20130196867 | COMBINATORIAL POST-TRANSLATIONALLY-MODIFIED HISTONE PEPTIDES, ARRAYS THEREOF, AND METHODS OF USING THE SAME - The present invention generally relates to combinatorial post-translationally-modified histone peptides and arrays thereof. The invention further relates to methods of using the same. | 08-01-2013 |
20130197924 | METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR EVALUATING A HOSPITAL PATIENT'S RISK OF MORTALITY - A method for evaluating a hospital patient's risk of mortality includes collecting data from physiologic signals generated by patient monitors, physiologic signals of organ function, and demographic information for a patient. A measure of the variability of at least one of the physiologic signals is determined. Data and the measure of variability are analyzed to determine whether a value for a particular physiologic or demographic variable falls within a critical interval for the variable that indicates that the value is predictive of mortality or survival. Each time a value for a physiological or demographic variable for the patient falls within a critical interval, the occurrence of an event for the patient is recorded. The number of events for the patient is counted over a time period. Output perceptible by human user that indicates the patient's risk of mortality or likelihood of survival is generated based on the count. | 08-01-2013 |
20130203799 | FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS - Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with farnesyltransferase inhibitors. | 08-08-2013 |